If you have been reading about GLP-1 receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-06. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
=== Animals === For mice, the dose at which acute toxicity occurs for intravenous administration is 40 mg/kg and for subcutaneous injection (injection in the layer of skin directly below the dermis and epidermis) this is 380 mg/kg. The lethal dose of dimethocaine for a mouse is 0.3 g per kilogram body weight. An abdominal constriction test was performed in mice, using doses of 5, 10, and 20 mg/kg of dimethocaine which were administered subcutaneously. This test showed induced dose-dependent antinociceptive responses, which are processes that block detection of a painful or injurious stimulus by sensory neurons. Impairment of memory processes was found to be a toxic effect in the elevated plus-maze test in mice.
=== Novo Nordisk Foundation === On March 1, 2021, Thomsen was appointed CEO of the Novo Nordisk Foundation, a philanthropic organization that funds research in health, life sciences, and sustainability.
== "Insulin" == "In 1920 the diagnosis of diabetes, particularly in the young and the very young, was essentially a death sentence." "The discovery of insulin represents a real breakthrough that has revolutionized both the therapy and the prognosis of people with diabetes ... Before insulin, diabetes was a dreadful condition associated with bad prognosis and miserable quality of life ... [progressing to] the ineluctable coma-death sequence. In 1889, Joseph von Mering and Oskar Minkowski reported that, in every case, the complete removal of an experimental dog's pancreas produced severe and fatal diabetes. They hypothesized that the consequent diabetic state was "due to loss of an 'internal secretion' of the pancreas rather than [to a loss] of the pancreatic exocrine secretion" (GL.2, p.2). Over the ensuing years, as the endocrine functions of the pancreas (glucagon, insulin, etc.), rather than its exocrine functions (pancreatic juice, etc.), were becoming increasingly better understood, "many investigators [had] endeavoured to obtain some beneficial effect in diabetes mellitus: either by feeding pancreas, or by administration of pancreatic extracts" (FB.2, p.141). The complete chemical structure of insulin was eventually determined by Frederick Sanger and Edward Thompson in 1953 (FS.2; FS.3): and, in 1965 (YW.1; YS.1), the team led by Wang Yinglai (王应睐/王應睞) was not only the first to create synthetic insulin, but was also, in the process, the first to produce a biologically active organic compound from inorganic chemicals.
Sources: en.wikipedia.org
A Type III civilization should be detectable because of the large amount of radiation captured on a galaxy-wide scale. Calissendorff suggests using 75% of the total light emitted by a galaxy to determine that a Type III civilization uses many Dyson spheres. If only three or four of these spheres occupy the galaxy, it does not necessarily mean that the civilization has reached Type III, and it may still be in transition; however, such civilizations may remain beyond the reach of our understanding and instruments. Semay observes that "a Type III civilization should not be confused with what science fiction writers call a 'galactic empire'", knowing that it can only exist if interstellar travel is achieved. Semay argues that there is no evidence that this will ever be possible. Based on Dyson's calculations, Semay believes that such a journey would take three centuries, with an average distance between stars of about 7 light years. Overall, the speed of the colonization front, which ranges from 4×10−4 to 5×10−3 light-years/year, would result in humanity spreading throughout the galaxy in a period of 16 to 200 million. "A Type III civilization, having thus "domesticated" its galaxy by building a large number of Dyson spheres, would be detectable over intergalactic distances of several million light-years." A Type III civilization could theoretically live inside a supermassive black hole, in a stable periodic orbit, which would make it completely undetectable, according to V. I. Dokuchaev.
Mahathir visited South Africa three times during his tenure as prime minister: a private visit in April 1994 to congratulate Mandela, an official visit in August 1995, and another in May 1997 when he received the Order of Good Hope. On 27 August 2013, the Mahathir Global Peace Foundation honoured Mandela with the Mahathir Award for Global Peace. In the same year as Mandela's passing, Mahathir expressed his deep sorrow, calling Mandela a great leader who dedicated his life to social justice. He admired Mandela's magnanimity, noting that despite years of imprisonment, he focused on reconciliation and sharing opportunities between blacks and whites. Mahathir also paid his last respects to Mandela in Pretoria, where he attended as a personal representative of Malaysia.
== Sources == The main source of atmospheric BaP is residential wood burning. It is also found in coal tar, in automobile exhaust fumes (especially from diesel engines), in all smoke resulting from the combustion of organic material (including cigarette smoke), and in charbroiled food. Data collected in 2024 by the European Environment Agency from all, except Portugal, EU-27 Member States as well as from Norway and Switzerland showed that the highest concentrations of BaP were found in eastern Europe and Italy, mainly associated with residential heating using coal, wood or derivatives. Methods of identifying BaP in foods have advanced over the years but difficulties remain in balancing speed with accuracy. Established methods include gas chromatography–mass spectrometry and high-performance liquid chromatography with fluorescence detection. A 2001 National Cancer Institute study found levels of BaP to be significantly higher in foods that were cooked well-done on the barbecue, particularly steaks, chicken with skin, and hamburgers: Cooked meat products have been shown to contain up to 4 ng/g of BaP, and up to 5.5 ng/g in fried chicken and 62.6 ng/g in overcooked charcoal barbecued beef. In 2008 the European Food Safety Authority stated that BaP was the only PAH that was regulated in food at the time. However, they stated it was not a suitable standalone indicator for the occurrence of PAHs in food and recommended using the sum of either four or eight PAHs as more suitable indicators for that matter.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.